Project Grant R16AI189462
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $158K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Norfolk, VA 23529, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Old Dominion University $1.322 million in funding on April 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms by which pathogenic Rickettsia species manipulate macrophage mitochondrial function and evade host immune responses. The award funds two research aims: determining how pathogenic spotted fever group rickettsia remodel mitochondrial dynamics in macrophages through...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases awarded $583,822 to the University of Texas at Arlington on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacterial pathogens evade thymineless death during anti-folate antibiotic treatment. The research uses Listeria monocytogenes as a model organism to characterize three evasion pathways: the role of cyclic di-AMP (c-di-AMP) and its interaction with the PII family protein PstA...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $233,125 on May 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the bacterial pathogen Legionella manipulates host cell peroxisomes to evade immune defenses. The research focuses on elucidating the molecular mechanisms by which Legionella alters peroxisome biology and recruits peroxisomes to its replication vacuole, with emphasis on identifying...
- The National Institute of Allergy and Infectious Diseases awarded the University of Toledo $768,796 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify immunoprotective antigens for preventing Lyme disease caused by Borrelia burgdorferi. The research will evaluate attenuated bacterial mutants as vaccine candidates, building on the recipient's prior identification of a BB strain lacking a chemotaxis-related gene that is rapidly cleared from...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded the University of Wisconsin - Madison $1,591,093 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the role of c-di-AMP (CDA) in Listeria monocytogenes pathogenesis. The research examines how CDA, an essential nucleotide second messenger for bacterial growth and infection, attenuates virulence in important pathogens. While CDA accumulation is widely reported to reduce...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $144,196 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into the functional role and biophysical characterization of the disordered N-terminal domain from the Borna disease virus phosphoprotein. The project, led by Principal Investigator Madison A. Stringer, combines biochemical and biophysical techniques to characterize the N-terminal...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $806,000 on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of secreted bacterial effectors in Group B Streptococcus (GBS) intestinal colonization and systemic neonatal infection. The research examines how GBS type VII secretion system effectors promote intestinal dysbiosis, impair immune responses, disrupt intestinal barrier function, and...
- The National Institute of Allergy and Infectious Diseases awarded Northeastern University $100,228 on December 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of G-quadruplex DNA structures in the antigenic variation mechanism of Borrelia burgdorferi, the causative agent of Lyme disease. The research addresses the molecular mechanism by which B. burgdorferi evades host adaptive immune defenses through antigenic variation—reshaping outer...